# Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

> **NCT01769781** · PHASE4 · COMPLETED · sponsor: **Centre for Endocrinology and Reproductive Medicine, Italy** · enrollment: 70 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** anastrazole
- **DRUG:** GnRH analog alone

## Key facts

- **NCT ID:** NCT01769781
- **Lead sponsor:** Centre for Endocrinology and Reproductive Medicine, Italy
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769781, "Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01769781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*